Use of AUC7 adjuvant carboplatin in patients with stage I seminoma: systematic review of the literature. Issue 2 (March 2018)

• Record Type: Journal Article
• Authors: Siracusano, Salvatore; Diminutto, Alberto; Porcaro, Antonio Benito; Cerruto, Maria Angela; Artibani, Walter
• Is Part Of: Tumori. Volume 104:Issue 2(2018)
• Page Start: 83
• Page End: 87
• Publication Date: 2018-03
• Subjects: Adjuvant -- AUC7 -- Carboplatin -- Relapse -- Seminoma; Cancer -- Periodicals; 616.994
• DOI: 10.5301/tj.5000577
• Languages: English
• ISSNs: 0300-8916

Abstract

Purpose: Among the adjuvant options to be proposed to patients with stage I seminoma after orchiectomy, the administration of a single cycle of carboplatin, at the dosage reaching an area under the curve of 7 mg/mL/min (AUC7), is a relatively recent introduction in clinical practice. Methods: On April 1, 2016, we performed a systematic review of the literature to identify studies on the use of AUC7 carboplatin in the adjuvant setting for stage I seminoma patients. The studies were identified by searching the PubMed electronic database from July 2005 up to April 2016. The aim of this review is to clarify the state of art of this adjuvant option. Results: Adjuvant AUC7 carboplatin is an effective adjuvant treatment, able to reduce relapse rate in stage I seminoma patients. The heterogeneity of the methods for estimation and measurement of glomerular filtration rate represents an important issue in the administration of the optimal dose of carboplatin. Even with the lack of validated prognostic factors for relapses, a risk-adapted choice is commonly used to identify the optimal patient to be proposed this treatment. Conclusions: One cycle of AUC7 carboplatin is an effective, feasible, and safe adjuvant option to be discussed with stage I seminoma patients.